Weiguo Ye Buys Shares of Gyre Therapeutics, Inc. $GYRE
Key Points
- Weiguo Ye bought 2,800 shares of Gyre Therapeutics, Inc. ($GYRE) worth $2,100.
- $GYRE last traded around $5.86.
Weiguo Ye, Chief Operating Officer at Gyre Therapeutics, Inc. ($GYRE), bought 2,800 shares at an average price of $0.75, for a total transaction of $2,100. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Gyre Therapeutics, Inc. ($GYRE) Stock
Gyre Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.